We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aveanna (AVAH) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Read MoreHide Full Article
Analysts on Wall Street project that Aveanna Healthcare (AVAH - Free Report) will announce quarterly earnings of $0.20 per share in its forthcoming report, representing an increase of 33.3% year over year. Revenues are projected to reach $683.17 million, increasing 9.8% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Aveanna metrics that are commonly tracked and projected by analysts on Wall Street.
It is projected by analysts that the 'Revenue- PDS' will reach $548.10 million. The estimate indicates a change of +6.5% from the prior-year quarter.
Analysts expect 'Revenue- MS' to come in at $48.46 million. The estimate points to a change of +7.5% from the year-ago quarter.
The consensus estimate for 'Revenue- HHH' stands at $69.43 million. The estimate indicates a change of +11.2% from the prior-year quarter.
The consensus among analysts is that 'Hours - PDS' will reach 12511 hours. Compared to the current estimate, the company reported 11822 hours in the same quarter of the previous year.
Based on the collective assessment of analysts, 'Revenue rate - MS' should arrive at $509.80 . Compared to the current estimate, the company reported $495.43 in the same quarter of the previous year.
The combined assessment of analysts suggests that 'Unique patients served (UPS) - MS' will likely reach 95 . The estimate compares to the year-ago value of 91 .
According to the collective judgment of analysts, 'Revenue rate - PDS' should come in at $43.81 . The estimate compares to the year-ago value of $43.51 .
The collective assessment of analysts points to an estimated 'Gross Margin- PDS' of $156.54 million. The estimate is in contrast to the year-ago figure of $149.27 million.
Analysts forecast 'Gross Margin- MS' to reach $21.68 million. Compared to the current estimate, the company reported $20.27 million in the same quarter of the previous year.
Analysts predict that the 'Gross Margin- HHH' will reach $37.15 million. Compared to the current estimate, the company reported $33.28 million in the same quarter of the previous year.
Over the past month, shares of Aveanna have returned +8.2% versus the Zacks S&P 500 composite's -5.6% change. Currently, AVAH carries a Zacks Rank #2 (Buy), suggesting that it may outperform. the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Aveanna (AVAH) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Analysts on Wall Street project that Aveanna Healthcare (AVAH - Free Report) will announce quarterly earnings of $0.20 per share in its forthcoming report, representing an increase of 33.3% year over year. Revenues are projected to reach $683.17 million, increasing 9.8% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Aveanna metrics that are commonly tracked and projected by analysts on Wall Street.
It is projected by analysts that the 'Revenue- PDS' will reach $548.10 million. The estimate indicates a change of +6.5% from the prior-year quarter.
Analysts expect 'Revenue- MS' to come in at $48.46 million. The estimate points to a change of +7.5% from the year-ago quarter.
The consensus estimate for 'Revenue- HHH' stands at $69.43 million. The estimate indicates a change of +11.2% from the prior-year quarter.
The consensus among analysts is that 'Hours - PDS' will reach 12511 hours. Compared to the current estimate, the company reported 11822 hours in the same quarter of the previous year.
Based on the collective assessment of analysts, 'Revenue rate - MS' should arrive at $509.80 . Compared to the current estimate, the company reported $495.43 in the same quarter of the previous year.
The combined assessment of analysts suggests that 'Unique patients served (UPS) - MS' will likely reach 95 . The estimate compares to the year-ago value of 91 .
According to the collective judgment of analysts, 'Revenue rate - PDS' should come in at $43.81 . The estimate compares to the year-ago value of $43.51 .
The collective assessment of analysts points to an estimated 'Gross Margin- PDS' of $156.54 million. The estimate is in contrast to the year-ago figure of $149.27 million.
Analysts forecast 'Gross Margin- MS' to reach $21.68 million. Compared to the current estimate, the company reported $20.27 million in the same quarter of the previous year.
Analysts predict that the 'Gross Margin- HHH' will reach $37.15 million. Compared to the current estimate, the company reported $33.28 million in the same quarter of the previous year.
View all Key Company Metrics for Aveanna here>>>Over the past month, shares of Aveanna have returned +8.2% versus the Zacks S&P 500 composite's -5.6% change. Currently, AVAH carries a Zacks Rank #2 (Buy), suggesting that it may outperform. the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .